Understanding this is the key to understanding immunotherapy. The goal is not to add a new weapon to the fight – it is to restore the immune system’s ability to recognise what it has been manipulated into ignoring. Dendritic cell immunotherapy does exactly that.
- Ahmedabd: 4th Floor, Galaxy Building, Law Garden, Opp. National Handloom C.G. Road
- Mumbai : Ved Hospital, Meghdoot, 6 SH Paralkar Marg, Dadar West, Shivaji Park
- +91 - 96014 79202
Complete Patient Guide · Clinically Reviewed
Dendritic Cell Immunotherapy - What It Is, How It Works, and Whether It's Right for You
Written by Dr. Vikesh Shah, MD (AIIMS), this patient guide explains dendritic cell immunotherapy in simple, easy-to-understand language, helping patients and families make informed decisions about cancer care.
Questions about your specific case? Dr. Shah reviews every case personally.
Your Immune System
Section 1 of 9
Before understanding immunotherapy, it is important to understand the role of the immune system. The immune system is a complex network of cells and signals that continuously monitors the body for abnormal or damaged cells.
Every day, normal cells divide, and occasionally some of these divisions result in abnormal cells. In many cases, the immune system identifies and removes these abnormal cells before they can grow or spread.
Cancer may develop when abnormal cells are able to avoid immune detection or suppress immune responses. This does not always mean the immune system is weak; rather, cancer cells can develop mechanisms that allow them to evade immune surveillance.
The key players – who does what in your immune system
To understand how immunotherapy works, it is important to know the main cells of the immune system and their roles in protecting the body against abnormal or cancerous cells.
Dendritic Cells
Dendritic cells are key immune cells responsible for identifying abnormal cells and processing their antigens. They present this information to other immune cells, helping the body recognize what needs to be targeted. They play a central role in immunotherapy approaches.
T-Cells (Killer T-cells)
T-cells are immune cells that directly attack and destroy infected or abnormal cells once they are activated. They are a major component of the body’s targeted immune response against cancer cells.
B-Cells
B-cells produce antibodies, which are proteins that bind to specific targets on foreign or abnormal cells. This helps mark them for destruction by other immune cells.
Natural Killer (NK) Cells
Natural killer cells are part of the innate immune system. They can recognize and destroy abnormal cells without prior exposure or activation, providing rapid immune defense.
Macrophages
Macrophages are immune cells that remove dead cells, cellular debris, and pathogens by engulfing and digesting them. They also help regulate immune activity by releasing signaling molecules.
Helper T-Cells
Helper T-cells coordinate immune responses by activating other immune cells and supporting a sustained immune reaction against threats such as infections or abnormal cell growth.
How cancer hides from your immune system
Cancer cells can avoid detection by changing or hiding the surface markers that normally identify them as abnormal. They may also release signals that reduce immune activity and create a tumor environment that suppresses immune response. This process is called immune evasion, and it allows cancer cells to grow even when the immune system is working normally.
Dendritic Cell
Section 2 of 9
Most people have never heard of dendritic cells until they learn about cancer immunotherapy. These specialized immune cells play an important role in helping the body recognize and respond to abnormal cells.
The Dendritic Cell
Named for its tree-like shape. The branching arms are sensors — constantly sampling the environment for molecular threats.
What do they actually do?
Dendritic cells are antigen-presenting cells. In plain language: they capture the molecular fingerprint of a threat — a virus, a cancer cell, a bacterium — and carry that fingerprint to your lymph nodes, where they show it to T-cells and say: “This is the enemy. Learn it. Hunt it.”
Why do they matter for cancer specifically?
In cancer patients, dendritic cells often fail in this briefing role — either because the cancer suppresses them, or because they never had a clean, undistorted sample of the cancer’s signature to work with. Immunotherapy solves this by preparing the dendritic cells outside the body, away from the tumour’s interference.
Are they from my own body?
Yes – entirely. We start with monocytes from your own blood. These are the precursor cells that, given the right conditions, mature into dendritic cells. Because they come from you, your body does not recognise them as foreign and does not reject them.
The reason dendritic cells are so central to this therapy is precisely because of their role as commanders. A killer T-cell is powerful — but it needs to be told who the enemy is before it can act. A dendritic cell provides that critical briefing. Without it, T-cells pass by cancer cells without acting. With it, they pursue them with precision.
Treatment Process
Section 3 of 9
Dendritic cell immunotherapy is a personalized treatment that uses your own immune cells. Here’s what you can expect during the process.
01 PHASE
02 PHASE
03 PHASE
Blood Collection
The first step is a simple blood draw at the hospital. This is not a bone marrow biopsy. It is not a surgical procedure. It is quick, straightforward, and no different from what you would experience during a routine check-up.
Inside that blood are mononuclear cells. These are white blood cells that circulate through the bloodstream on patrol. They are the raw material from which everything that follows is built. At this stage, they don't yet know anything specific about your cancer — that comes next.
Laboratory Preparation
Your blood sample goes to the laboratory, and this is where careful, controlled work begins. The immune cells are separated from the rest of your blood and placed in a clean, protected environment — completely away from the influence of the cancer in your body.
Over the following days, these cells are carefully guided to grow and mature into fully active dendritic cells. Once they have matured, they are introduced to information about your specific cancer — so they know exactly what to look for when they return to your body.
Think of it this way: your cells are like detectives who have never seen the suspect. The lab phase gives them everything they need — a clear picture of who the enemy is — so they can recognise it the moment they're back inside you.
Bringing the Cells Back — Activating Your Immune Response
When the cells are ready, you come in to the hospital for a session. The trained dendritic cells are given back into your body. No anaesthesia is needed, and no overnight stay is required.
Once inside your body, the dendritic cells travel through your lymphatic system to your lymph nodes — the regional headquarters of your immune response. There, they show your immune system a clear picture of the cancer. The immune cells are activated, they multiply, and they begin searching your body for cells that match that picture.
This is the moment the immune system genuinely begins to fight the cancer as it should have been fighting it all along. The response is not immediate — the immune system takes time to mobilise, much as it does after a vaccination. But what develops over the following weeks and months is a targeted, persistent anti-cancer immune response built entirely from your own biology.
A note on the number of sessions
There is no fixed number of sessions. Dr. Vikesh Shah creates a personalized treatment plan based on your condition, overall health, and individual needs. Your progress is reviewed regularly, and the treatment schedule may be adjusted accordingly.
Who Can Benefit
Section 4 of 9
This is the question we are asked most often, and it deserves a careful, honest answer rather than a simple yes or no.
Patients who are often good candidates
- Those who have completed chemotherapy or radiation and want to strengthen their immune response going forward
- Patients at advanced stages who want to add an immune-based approach alongside or after standard treatment
- Those whose cancer has not responded well to previous treatments, or who cannot tolerate further high-dose therapy
Cases that need individual clinical evaluation
- Patients on high-dose immunosuppressant medications, such as those taken after organ transplants
- Those with active autoimmune conditions — this requires careful clinical evaluation, not automatic exclusion
None of these are automatic exclusions. They are factors Dr. Shah weighs carefully in the consultation before making any recommendation.
On age and performance status
There is no upper age limit for dendritic cell immunotherapy. The treatment has been used in patients in their seventies, eighties and nineties.
Which Cancers Can Be Treated
Section 5 of 9
Because dendritic cell immunotherapy targets the molecular fingerprint of your specific cancer — not a fixed drug target — it can potentially be considered across a much wider range of cancer types than most people assume.
Lung Cancer (NSCLC)
Lung Cancer (SCLC)
Breast Cancer
Colorectal Cancer
Gastric Cancer
Oesophageal Cancer
Pancreatic Cancer
Liver Cancer
Bile Duct Cancer
Kidney Cancer
Bladder Cancer
Gallbladder Cancer
Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Chronic Lymphocytic Leukaemia
Multiple Myeloma
Myelodysplastic Syndrome
Acute Myeloid Leukaemia
Waldenstrom's Macroglobulinaemia
Oral Cancer
Tongue Cancer
Throat (Pharyngeal) Cancer
Laryngeal Cancer
Thyroid Cancer
Salivary Gland Cancer
Nasopharyngeal Cancer
Jaw & Sinus Cancer
Ovarian Cancer
Cervical Cancer
Uterine (Endometrial) Cancer
Fallopian Tube Cancer
Vulval Cancer
Vaginal Cancer
Prostate Cancer
Testicular Cancer
Renal Cell Carcinoma
Urothelial Carcinoma
Penile Cancer
Adrenal Gland Cancer
Melanoma
Merkel Cell Carcinoma
Basal Cell Carcinoma
Squamous Cell Carcinoma of Skin
Soft Tissue Sarcoma
Osteosarcoma (Bone)
Ewing's Sarcoma
Glioblastoma (GBM)
Astrocytoma
Oligodendroglioma
Medulloblastoma
Ependymoma
Brain Metastases
Don't see your specific cancer type listed here? The list above is a guide — not a complete boundary. Bring your biopsy and scan reports to a consultation and Dr. Shah will assess individually.
Immunotherapy vs Chemotherapy: Understanding the Differences
Section 6 of 9
Chemotherapy is one of the most powerful tools in oncology. It has saved millions of lives, and we would never dismiss it. But it was designed in a different era with a different logic — target everything that divides fast, and hope the cancer suffers more than the patient does. It is an approach that works, but it carries a significant cost.
Dendritic cell immunotherapy is built around a completely different logic: rather than adding a toxic agent, strengthen and redirect what your body already has. The comparison below is not meant to say one is better than the other in every case. It is meant to help you understand why they are fundamentally different tools — and why many patients benefit from both.
|
Factor
|
Chemotherapy
|
Radiation Therapy
|
Dendritic Cell Immunotherapy
|
|---|---|---|---|
|
How it works
|
Kills fast-dividing cells — cancer and healthy tissue alike
|
Damages DNA of cells in the radiation field, including surrounding normal cells
|
Trains your own immune system to identify and destroy cancer cells specifically
|
|
Precision
|
Systemic — affects the whole body
|
Local — limited to the target area
|
Targeted — directed at your cancer's unique molecular fingerprint
|
|
Common side effects
|
Hair loss, nausea, vomiting, fatigue, bone marrow suppression, infection risk
|
Localised tissue damage, fatigue, skin irritation in the treated area
|
Mild — low-grade fever, brief fatigue, local injection site redness (usually 24–48 hrs)
|
|
Can it work at Stage 4?
|
Yes, but toxicity tolerance becomes a limiting factor
|
Limited — spread of cancer reduces local control applicability
|
Yes — immune activation is systemic and not limited by tumour location
|
|
Immune memory
|
No — effect ends when treatment ends
|
No — effect is local and structural
|
Yes
|
|
Can be combined with other treatment?
|
Yes — often used in combination
|
Yes — often combined with chemotherapy
|
Yes, can be used alongside other treatments
|
Treatment decisions should always be made by a qualified doctor based on individual medical reports, cancer type, and overall health condition. This information is intended to provide general understanding, not to replace medical advice.
Side Effects of Dendritic Cell Immunotherapy: What to Expect
Section 7 of 9
This is the section most patients turn to first, and understandably so. After going through chemotherapy or radiation, the prospect of another treatment that might bring a new set of difficult side effects is understandably worrying. The short answer is: most patients find the side effects of dendritic cell immunotherapy to be mild and short-lived.
The reason comes down to the fundamental difference in how the treatment works. Chemotherapy introduces a foreign toxic agent into the body. Dendritic cell immunotherapy introduces cells your body already recognises as its own. The immune system does not mount a major inflammatory reaction against itself — it responds with the measured, targeted activation it was designed to produce.
Commonly Reported Side Effects
Mild, short-lived — signs of immune activation
In some patients, the following temporary effects may occur:
- Mild fever (around 37.5°C to 38.5°C), usually within 24 hours of treatment
- Mild fatigue lasting one to two days
- Mild redness, swelling, or warmth at the injection site
These effects are generally short-lived and resolve without additional treatment.
What is not affected
Hair loss does not occur with dendritic cell immunotherapy — this is one of the most significant quality-of-life differences from chemotherapy. Bone marrow suppression, severe nausea, and vomiting are not associated with this treatment. The gut lining, which is heavily damaged by chemotherapy, is not directly affected. Most patients continue their normal daily routines throughout a course of immunotherapy.
What the Research Says About Dendritic Cell Immunotherapy
Section 8 of 9
Cancer immunotherapy is not a new idea — the concept has been studied for over four decades. But it is a rapidly maturing field. The approval of the first dendritic cell-based therapy (Sipuleucel-T, for prostate cancer) by the US FDA in 2010 was a landmark moment that validated the scientific foundation underlying this entire approach.
Since then, the published evidence has grown significantly. Hundreds of clinical trials have explored dendritic cell immunotherapy across cancer types, and while the field is still evolving — as all serious medicine is — the core mechanism is well-established, well-understood, and supported by peer-reviewed research.
2010
Year of first FDA-approved dendritic cell therapy (Sipuleucel-T)
600+
Clinical trials published globally on dendritic cell cancer therapy
3
Peer-reviewed papers published by Dr. Shah in EJMC and JAMDSR
20+
Years of accumulated global clinical evidence in this field
A realistic note on expectations
Dendritic cell immunotherapy is not considered a standalone cure for cancer. It is being studied as part of broader cancer care approaches, often in combination with established treatments. Current research focuses on its potential role in supporting immune system activity, improving disease control in selected cases, and enhancing overall treatment strategies under medical supervision.
Questions Patients Ask Most Often
Section 9 of 9
These are the questions that come up in nearly every first consultation. We have tried to answer them the way Dr. Shah answers them in the room — plainly, honestly, without hiding behind medical language.
1. How does immunotherapy treatment work?
Immunotherapy works by helping the immune system recognize and respond more effectively to cancer cells.
2. Is immunotherapy better than chemotherapy?
Immunotherapy and chemotherapy work in different ways. In some cases, they may be used separately or together depending on the patient’s condition and treatment plan.
3. Who can receive immunotherapy treatment?
Eligibility for immunotherapy depends on several factors, including cancer type, stage, overall health, and medical history. A specialist evaluates each case individually before recommending treatment.
4. Does immunotherapy have side effects?
Some patients may experience mild side effects such as fever, fatigue, or body aches. However, side effects can vary depending on the type of immunotherapy and individual response.
5. What types of cancer can immunotherapy be used for?
Immunotherapy may be considered for several types of cancer depending on clinical evaluation, including lung, breast, colorectal, prostate, and others.
ImmunoHope · Ahmedabad & Mumbai
Still Have Questions? The Best Answers Come from a Real Consultation.
Bring your most recent reports. Dr. Shah personally reviews every case and gives you an honest, individual assessment — whether or not immunotherapy turns out to be the right path for you.
Consultations available in-clinic at Ahmedabad or Mumbai, by phone, or by video. No pressure. No commitment required.